<DOC>
	<DOCNO>NCT02824003</DOCNO>
	<brief_summary>The purpose study evaluate effect ISIS 449884 ( ISIS-GCGRRX ) Hepatic Lipid Glycogen Content patient Type 2 Diabetes treat Metformin .</brief_summary>
	<brief_title>Study Evaluate Effect ISIS GCGRRx Hepatic Lipid Glycogen Content Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female , age 18 75 BMI ≥ 25.0 kg/m2 &lt; 36.0 kg/m2 HbA1c ≥ 7.5 % ≤ 10.5 % Type 2 Diabetes Mellitus stable dose Metformin . Patients must stable dose oral metformin ( least 1000 mg/day ) minimum 3 month prior screen evaluation require continue stable dose metformin throughout study . Patients stable dose metformin plus sulfonylurea ( SU ) metformin plus dipeptidyl peptidaseIV ( DPPIV ) inhibitor minimum 3 month prior Screening evaluation may allow Agree conduct homebased ( fast ) blood glucose test direct Clinically significant abnormality medical history physical exam Show evidence uncorrected hypothyroidism hyperthyroidism History liver transplantation renal dialysis History liver disease History great 3 episode severe hypoglycemia within 6 month screen Treatment antidiabetic drug ( ) metformin , SU DPPIV within 3 month screen History diabetic ketoacidosis Any significant illness condition may interfere patient participate complete study Inability unwillingness comply protocol study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>